陳柏謙 李瑛
【摘要】 目的:探討分析大柴胡湯聯(lián)合柳氮磺胺吡啶腸溶片治療潰瘍性結(jié)腸炎的效果。方法:將2018年1-12月本院收治的86例潰瘍性結(jié)腸炎患者隨機分為觀察組和對照組,觀察組給予大柴胡湯聯(lián)合柳氮磺胺吡啶腸溶片治療,對照組僅給予柳氮磺胺吡啶腸溶片治療,比較兩組臨床療效、治療前后癥狀評分、黏膜評分、炎性因子水平及不良反應發(fā)生情況。結(jié)果:觀察組總有效率為95.35%,較對照組的79.07%顯著提高(P<0.05)。兩組治療前腹瀉、腹痛、膿血便及里急后重癥狀評分比較,差異均無統(tǒng)計學意義(P>0.05);兩組治療后各癥狀評分均顯著下降,且觀察組各癥狀評分下降更顯著(P<0.05)。兩組治療前黏膜評分比較,差異無統(tǒng)計學意義(P>0.05);兩組治療后黏膜評分均顯著性下降,且觀察組黏膜評分下降更顯著(P<0.05)。兩組治療前IL-1β、IL-6、TNF-α水平比較,差異均無統(tǒng)計學意義(P>0.05);兩組治療后各指標水平均顯著下降,且觀察組各指標水平下降更顯著(P<0.05)。兩組不良反應發(fā)生率比較,差異無統(tǒng)計學意義(P>0.05)。結(jié)論:大柴胡湯聯(lián)合柳氮磺胺吡啶腸溶片治療潰瘍性結(jié)腸炎可提高臨床療效,改善患者的臨床癥狀,促進結(jié)腸黏膜恢復,提高患者生活質(zhì)量。
【關(guān)鍵詞】 大柴胡湯 柳氮磺胺吡啶腸溶片 潰瘍性結(jié)腸炎
Effect of Dachaihu Decoction Combined with Sulfasalazine Enteric-coated Tablets in the Treatment of Ulcerative Colitis/CHEN Boqian, LI Ying. //Medical Innovation of China, 2020, 17(15): 0-069
[Abstract] Objective: To explore the effect of Dachaihu Decoction combined with Sulfasalazine Enteric-coated Tablets in the treatment of patients with ulcerative colitis. Method: A total of 86 patients with ulcerative colitis who treated in our hospital from January to December 2018 were randomly divided into the observation group and the control group. The patients in the observation group were treated with Dachaihu decoction combined with Sulfasalazine Enteric-coated Tablets, the control group was treated only with Sulfasalazine Enteric-coated Tablets. The clinical efficacy, symptom score, mucosal score, level of inflammatory factors and occurrence of adverse reactions of two groups were compared. Result: The total effective rate in the observation group was 95.35%, which was significantly higher than 79.07% of the control group (P<0.05). The scores of diarrhea, abdominal pain, bloody purulent stool and tenesmus of two groups were compared, there were no significant differences (P>0.05). After treatment, the scores of symptoms of two groups decreased significantly, and the observation group decreased more significantly (P<0.05). The mucosal scores of two groups before treatment compared, there was no significant difference (P>0.05). The mucosal scores of two groups decreased significantly after treatment, and the observation group decreased more significantly (P<0.05). There were no significant differences in the levels of IL-1β, IL-6, and TNF-α of two groups (P>0.05). The levels of indexes of two groups decreased significantly after treatment, and the observation group decreased more significantly (P<0.05). The incidence of adverse reactions of two groups compared, there was no significant difference (P>0.05). Conclusion: Dachaihu Decoction combined with Sulfasalazine Enteric-coated Tablets in the treatment of ulcerative colitis can improve the clinical efficacy, improve the clinical symptoms of patients, promote the recovery of colonic mucosa and improve the quality of life of patients.
我國傳統(tǒng)醫(yī)學認為潰瘍性結(jié)腸炎屬于“腹瀉、痢疾”的范疇,其病因主要為毒邪侵入,最為常見的是濕熱,濕熱大腸郁蒸,氣滯血瘀,臟腑不暢,互為孳生,血脈不暢損傷,生為膿血,但下痢紅而白,病為濕邪,性重濁,清除黏膩難,脾陽困阻,傷脾失運,濕熱內(nèi)蘊伺機而侵入,病情反復,難以治愈[14-15]。《類證治裁·痢疾》解釋:濕熱郁蒸、氣血凝滯致潰瘍性結(jié)腸炎,治療當以清熱,活血為主要原則[16]。本研究結(jié)果顯示:觀察組總有效率達95.35%,腹瀉、腹痛、膿血便、里急后重癥狀評分均顯著下降,黏膜評分顯著下降,差異均有統(tǒng)計學意義(P<0.05)。說明大柴胡湯聯(lián)合柳氮磺胺吡啶腸溶片治療潰瘍性結(jié)腸炎可提高臨床療效,改善患者的臨床癥狀,促進結(jié)腸黏膜的恢復,這主要是由于大柴胡湯主要由柴胡、白芍、黃芩、半夏、枳實、酒大黃、生姜組成,其中柴胡具有疏肝解郁,調(diào)節(jié)氣血之效,白芍補血養(yǎng)肝,止痛收汗之效,黃芩清熱解毒,燥濕涼血之效,半夏散結(jié)消腫,化痰燥濕,止嘔之效,枳實疏肝理氣,消痞散結(jié),酒大黃清熱解毒,生姜調(diào)節(jié)脾胃,止嘔健脾之效,全方共湊清熱解毒、活血降逆,疏肝解郁,理氣止痛和胃之效[17-18]。研究顯示:潰瘍性結(jié)腸炎發(fā)病與機體內(nèi)的炎性因子水平密切相關(guān)[19-20]。本研究結(jié)果顯示:觀察組IL-1β、IL-6、TNF-α指標水平均顯著下降(P<0.05)。說明大柴胡湯聯(lián)合柳氮磺胺吡啶腸溶片治療潰瘍性結(jié)腸炎可降低患者機體內(nèi)炎性因子水平,保護胃黏膜,也說明大柴胡湯可調(diào)節(jié)腸道菌群,平衡抗炎和促炎因子的平衡。
綜上所述,柴胡湯聯(lián)合柳氮磺胺吡啶腸溶片治療潰瘍性結(jié)腸炎可提高臨床療效,改善患者的臨床癥狀,促進結(jié)腸黏膜的恢復,提高患者生活質(zhì)量。
參考文獻
[1]王曉春,肖景東.中西醫(yī)治療潰瘍性結(jié)腸炎研究概況[J].中國民族民間醫(yī)藥,2020,29(2):40-42.
[2]劉博偉,肖偉,賈航,等.350例潰瘍性結(jié)腸炎患者臨床特征分析[J].胃腸病學和肝病學雜志,2019,28(1):92-95.
[3]范昊華,羅偉云.中西醫(yī)結(jié)合藥物治療潰瘍性結(jié)腸炎脾胃虛弱型的臨床對比觀察[J].中國醫(yī)藥科學,2020,10(4):40-42,134.
[4]李莉,費素娟,朱祖安,等.兩種用藥方案治療潰瘍性結(jié)腸炎的療效與安全性比較[J].中國處方藥,2019,17(10):104-105.
[5]梁鐙月,李桂賢,韋德鋒,等.中藥調(diào)節(jié)腸道菌群在潰瘍性結(jié)腸炎治療中的應用概述[J].山東中醫(yī)雜志,2020,39(2):195-198.
[6]徐杰.雙歧桿菌三聯(lián)活菌散輔助治療潰瘍性結(jié)腸炎的臨床效果及對炎癥因子水平的影響[J].中國醫(yī)學創(chuàng)新,2020,17(2):53-56.
[7]中華醫(yī)學會消化病學分會炎癥性腸病協(xié)作組.對我國炎癥性腸病診斷治療規(guī)范的共識意見[J].中華消化雜志,2007,12(8):545-550.
[8]司馬彥.柳氮磺吡啶配合半夏瀉心湯治療潰瘍性結(jié)腸炎50例療效觀察[J].中國肛腸病雜志,2020,40(1):32-33.
[9]麻瑞娟,茍金平.柳氮磺吡啶與復方甘草酸苷聯(lián)合治療潰瘍性結(jié)腸炎對其不良反應的影響[J].智慧健康,2019,5(29):100-101.
[10]羅舒丹,詹麗,楊娟,等.益生菌聯(lián)合美沙拉秦治療潰瘍性結(jié)腸炎的臨床療效及對血清炎癥指標的影響[J].中國微生態(tài)學雜志,2020,32(2):200-203.
[11] Gku A R F,Ozgur O.Inflammatory cytokine gene polymorphism profiles in Turkish patients with ulcerative colitis[J].Med Glas(Zenica),2015,12(1):33-39.
[12] Tagvaei T,Maleki I,Nagshvar F,et al.Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis[J].Intern Emerg Med,2015,10(3):1-8.
[13] Nielsen S T,Beninati L,Buonato C B.Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation[J].Scand J Gastroenterol,2018,23(3):272-276.
[14]李水康,李振飛.雙歧桿菌活菌膠囊聯(lián)合柳氮磺吡啶腸溶片治療潰瘍性結(jié)腸炎的效果及對患者血清炎癥因子水平的影響[J].中國醫(yī)學創(chuàng)新,2020,17(4):20-23.
[15]賴良彬,李觀慶,林兆輝,等.柳氮磺吡啶腸溶片結(jié)合毫火針治療潰瘍性結(jié)腸炎臨床觀察[J].實用中醫(yī)藥雜志,2019,35(4):443-444.
[16]張曉云,周文,劉馥春,等.寒熱并用在潰瘍性結(jié)腸炎臨床運用中的策略分析[J].中醫(yī)研究,2020,33(5):1-3.
[17]殷娟,唐西懷,賈晶晶.潰瘍性結(jié)腸炎患者的腸道菌群分布與血清TNF-α、IL-6水平的相關(guān)性[J].檢驗醫(yī)學與臨床,2019,16(23):3421-3423.
[18]高艷奎,申睿,朱向東,等.中醫(yī)藥治療潰瘍性結(jié)腸炎作用機制研究進展[J].中醫(yī)藥學報,2020,48(2):75-80.
[19]楊新建.大柴胡湯聯(lián)合隔姜灸對潰瘍性結(jié)腸炎患者外周血單核細胞Toll樣受體-4、核轉(zhuǎn)錄因子-κB信號通路的影響[J].河南中醫(yī),2019,39(11):1670-1674.
[20]鄒凌云.中西醫(yī)結(jié)合治療潰瘍性結(jié)腸炎42例臨床觀察[J].中國醫(yī)藥指南,2020,18(1):186-187.
(收稿日期:2020-04-02) (本文編輯:程旭然)